Shake-up at Valeant signals stunning fall from grace for J Michael Pearson
Pharmaceutical giant faces a growing list of questions from investors and regulators
Valeant shares slump on new SEC investigation
News comes as Canadian drug-maker pulled 2016 forecasts
Drugmaker Valeant pulls forecasts as Pearson returns
Chief executive back at the helm after two-month absence through illness but Robert Ingram retains chairman’s post
Elan urges shareholders to reject Royalty Pharma offer
Company says bid fails to properly value business
Elan’s board rejects Royalty Pharma bid
US investment firm last week lowered its bid for the drugmaker to $11.25 a share from an earlier $12 per share offer
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Election 2024
Full general election coverage including analysis and results for all 43 constituencies
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices